Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-12-10 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
北京植德律师事务所关于长春百克生物科技股份公司2024年第一次临时股东会的法律意见书
Regulatory Filings
2024-12-10 Chinese
长春百克生物科技股份公司2024年第一次临时股东会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2024 first extraordinary shareholders meeting of Changchun Baike Biotechnology Co., Ltd. It includes information about the meeting date, attendance, voting results on various proposals including amendments to the company charter, board and supervisory board elections, and legal witness statements. The content focuses on shareholder voting outcomes and meeting procedural compliance. There is no financial data, earnings information, or report publication notice. The document is not a full annual or interim report, nor a call transcript or capital update. It is a formal declaration of voting results from a shareholders meeting, matching the definition of Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is under 5,000 characters, but it contains substantive voting results, not just a notice of report publication, so it is not RPA or RNS.
2024-12-10 Chinese
长春百克生物科技股份公司关于完成董事会、监事会换届选举及聘任高级管理人员、证券事务代表的公告
Board/Management Information Classification · 100% confidence The document is an official announcement from Changchun Baike Biotechnology Co., Ltd. regarding the completion of the board of directors and supervisory board re-election, as well as the appointment of senior management and securities affairs representatives. It details the election results, names of newly appointed directors, supervisors, and senior management personnel, their terms, and related committee compositions. There is no financial data, earnings information, or report publication mentioned. The content focuses on changes in the company's board and senior management personnel. Therefore, this document fits the category of Board/Management Information (MANG). The document length is 5568 characters, which is sufficient for a detailed announcement rather than a brief notice or report publication announcement.
2024-12-10 Chinese
中信证券股份有限公司关于长春百克生物科技股份公司调整核心技术人员的核查意见
Regulatory Filings
2024-12-10 Chinese
长春百克生物科技股份公司关于调整核心技术人员的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the adjustment of core technical personnel at Changchun Baike Biotechnology Co., Ltd. It details the change in personnel status, the impact on the company, and includes a verification opinion from the sponsoring institution. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The content focuses on management and personnel changes specifically related to core technical staff, which aligns with announcements about changes in senior management or key personnel. Therefore, the document fits best under the category of Board/Management Information (MANG). The document length is 2032 characters, which is relatively short and consistent with an announcement rather than a full report.
2024-12-10 Chinese
长春百克生物科技股份公司2024年第一次临时股东会会议资料
AGM Information Classification · 95% confidence The document is titled as the "2024 First Extraordinary General Meeting (EGM) Meeting Materials" of Changchun Baike Biotechnology Co., Ltd. It contains detailed meeting notices, agenda, and multiple proposals for shareholder approval, including amendments to the company charter, governance system revisions, and board and supervisory committee elections. It includes candidate biographies and procedural details for the shareholder meeting. The content is typical of materials prepared and distributed for a shareholders' meeting to inform and guide voting on corporate governance matters. It is not a report of financial results, audit, or earnings, nor is it a simple announcement or regulatory filing. It is not a transcript or presentation but the actual meeting materials for the shareholders' meeting. Therefore, it fits the category of AGM Information (AGM-R). The document length and detail confirm it is the meeting materials themselves, not just an announcement or summary.
2024-11-29 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.